Seropositive rheumatoid arthritis confirmed by positive rheumatoid factor, with no documented specific joint site and no evidence of extra-articular organ or systemic involvement.
Verified May 8, 2026 · 5 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 7
- Region
- General
Documentation tips
What should appear in the chart to support M05.70.
Source · Editorial brief grounded in 5 cited references ↓
- Record the specific rheumatoid factor lab result (RF titer or positive/negative status) and the date of the confirming test to justify M05 over M06.
- Explicitly state that no organ or systemic involvement is present (no vasculitis, pericarditis, pleuritis, neuropathy, Felty's) — absence of findings must be documented, not assumed.
- If joint sites are identifiable at the encounter, name each affected joint and laterality in the assessment; this forces migration to a more specific M05.7x child code.
- Document current disease activity level (remission, low, moderate, high) and any DAS28 or CDAI score — supports medical necessity for biologic or targeted therapy authorizations.
- Record the treatment plan including current DMARDs or biologics; CMS biomarker testing LCD requires this context when M05.70 is used as a supporting diagnosis.
Related CPT procedures
Procedure codes commonly billed with M05.70. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M05.70 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Assigning M05.70 when specific joint involvement is documented in the same note — auditors expect site-specific M05.71x–M05.77x codes when laterality and joint are named.
- Using M05.70 for seronegative RA — if RF is negative or not documented as positive, the correct category is M06.0x, not M05.7x.
- Confusing M05.70 (unspecified site, no systemic involvement) with M05.60 (unspecified site, with organ/systems involvement) — the distinction hinges on extra-articular findings documented in the record.
- Defaulting to M05.70 when M05.79 (multiple sites) is more accurate — if the note lists three affected joints, M05.79 is the correct pick, not the unspecified-site code.
- Failing to exclude juvenile RA (M08.-) and RA of the spine (M45.-), both Type 1 excludes under M05 — do not assign M05.70 for these conditions.
Clinical context
Source · Editorial summary grounded in 5 cited references ↓
M05.70 is the fallback code within the M05.7x subcategory when the treating clinician documents seropositive RA (positive RF lab result) but has not specified which joint or anatomical site is affected, and the record contains no organ or systemic involvement (e.g., no rheumatoid vasculitis, pericarditis, pleuritis, neuropathy, or Felty's syndrome). The '0' sixth character signals unspecified site — not bilateral or multi-site. If multiple joints are documented, use M05.79. If a specific joint is named, use the corresponding site-specific code (M05.711–M05.779).
This code applies only when the rheumatoid factor is documented as positive. Seronegative RA routes to M06.0x, not M05.7x. Confirm the lab result is in the record before assigning any M05 code. CMS LCD A56541 (Biomarkers Overview) and A59536 (Molecular Biomarker Testing for RA targeted therapy) both list M05.70 as a supporting diagnosis code for biomarker-driven testing claims — having it coded correctly matters for coverage.
Avoid assigning M05.70 as a long-term primary code when the treating physician has documented specific joint involvement across multiple visits; auditors will flag the unspecified-site code as lacking specificity when the chart clearly names the affected joints. Use M05.70 when site is genuinely unknown or not yet localized at the time of the encounter.
Sibling codes
Other billable codes under M05.7 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 5 cited references ↓
01When is M05.70 appropriate versus M05.79?
02Can M05.70 be used if the rheumatoid factor result is pending?
03Does M05.70 cover extra-articular manifestations like rheumatoid nodules?
04Is M05.70 valid for a CMS biomarker testing claim?
05What MS-DRGs does M05.70 map to?
06Should M05.70 ever be sequenced as a secondary diagnosis during an orthopedic encounter?
07How does M05.70 differ from M05.9?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective Oct 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M05-M14/M05-/M05.70
- 03cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56541&ver=40
- 04cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=59536&ver=7
- 05aapc.comhttps://www.aapc.com/codes/icd-10-codes/M05.70
Mira AI Scribe
Mira AI Scribe captures the positive RF lab value (titer and date), the absence of documented organ or systemic involvement, and any joint regions mentioned in the encounter note. This prevents downcoding to the less specific M05.9 or miscoding to seronegative M06 categories, and flags when named joint sites push the encounter to a more specific M05.71x–M05.77x code rather than the unspecified-site fallback.
See how Mira captures M05.70 documentation